Insights
Research and perspectives on immunometabolism,
tumor microenvironments, and cell therapy engineering
![<h2 class="font_2">Introduction</h2>
<p class="font_8"><br></p>
<p class="font_8">Solid tumors create metabolically hostile environments that challenge the function and persistence of immune cells. One of the defining characteristics of the tumor microenvironment is hypoxia, a condition in which oxygen levels fall significantly below those found in normal tissues. Oxygen concentrations within tumors typically range from approximately 0.2% to 4%, considerably lower than normal tissue oxygen levels (physoxia) of 3–7.4%, and far below the ~21% found in standard cell culture conditions and atmospheric air (Bigos et al., 2024; Vaupel & Mayer, 2007).</p>
<p class="font_8"><br></p>
<p class="font_8">For T cells, oxygen availability is closely tied to metabolic activity, differentiation, and effector function. As immunotherapies such as CAR-T and tumor-infiltrating lymphocyte (TIL) therapies continue to advance, understanding how hypoxic conditions influence T cell biology has become increasingly important. The metabolic state of therapeutic immune cells can strongly influence their ability to persist, proliferate, and function within the tumor microenvironment (Scharping & Delgoffe, 2021; Longo et al., 2025).</p>
<p class="font_8"><br></p>
<p class="font_8">This article explores how hypoxia shapes T cell metabolism and function, and why oxygen levels represent an important parameter in the development and manufacturing of cell-based immunotherapies.</p>
<p class="font_8"><br></p>
<h2 class="font_2">Oxygen Gradients in Solid Tumors</h2>
<p class="font_8"><br></p>
<p class="font_8">Solid tumors frequently outgrow their vascular supply, creating regions with limited oxygen delivery. Tumor-associated blood vessels are often irregular and inefficient, resulting in heterogeneous oxygen distribution throughout the tumor mass (Bigos et al., 2024). Median tumor oxygen levels across cancer types range from approximately 0.3% to 4.2%, with most tumors exhibiting median oxygenation below 2%.</p>
<p class="font_8"><br></p>
<p class="font_8">These oxygen gradients create microenvironments where immune cells encounter conditions dramatically different from those experienced during ex vivo cell expansion. It is also worth noting that even normal tissue oxygen levels (physoxia, ~3–7%) are substantially lower than the 21% used in standard culture conditions, meaning manufacturing environments are metabolically mismatched with the in vivo context from the outset. In addition to hypoxia, immune cells in tumors must contend with nutrient depletion, acidic extracellular pH, and metabolic competition with rapidly proliferating cancer cells (Scharping & Delgoffe, 2021).</p>
<p class="font_8"><br></p>
<p class="font_8">Collectively, these conditions impose significant metabolic constraints on infiltrating T cells. Cells that cannot adapt to these stresses may lose functionality or undergo exhaustion, limiting the effectiveness of immune-mediated tumor clearance.</p>
<p class="font_8"><br></p>
<h2 class="font_2">Hypoxia-Inducible Signaling in T Cells</h2>
<p class="font_8"><br></p>
<p class="font_8">A central mediator of cellular responses to low oxygen is hypoxia-inducible factor-1α (HIF-1α). Under hypoxic conditions, HIF-1α becomes stabilized and translocates to the nucleus, where it regulates transcriptional programs involved in metabolism, survival, and stress adaptation.</p>
<p class="font_8">In T cells, HIF-1α influences several key processes including metabolic reprogramming, cytokine production, and differentiation pathways (Shi et al., 2025). Importantly, these effects are context-dependent. Under hypoxic conditions specifically, the HIF-1α–glycolysis axis has been shown to regulate IFN-γ production in activated T cells, a relationship that does not operate through the same mechanism under normoxic conditions (Shen et al., 2024). </p>
<p class="font_8"><br></p>
<p class="font_8">Additionally, HIF-1α is indispensable for CD8+ T cells to sustain glycolytic metabolism and execute effective tumor cell killing, underscoring its dual role as both a stress-response mediator and a positive effector of anti-tumor function (Shi et al., 2025).</p>
<p class="font_8"><br></p>
<p class="font_8">HIF-1α also drives upregulation of immune checkpoint ligands, particularly PD-L1, on tumor cells and stromal cells. This PD-L1 expression engages PD-1 on cytotoxic T cells, contributing to T cell exhaustion and reduced effector activity, a mechanism of direct relevance for immunotherapy design (Shi et al., 2025). Prolonged hypoxic signaling can further contribute to metabolic stress and immune dysfunction depending on the broader metabolic context (Shen et al., 2024).</p>
<p class="font_8"><br></p>
<p class="font_8"><a href="https://www.xcellbio.com/technology"><strong>Understanding how hypoxia influences these signaling pathways </strong></a>is therefore essential for predicting immune cell behavior within tumors.</p>
<p class="font_8"><br></p>
<h2 class="font_2">Metabolic Adaptation of T Cells to Hypoxia</h2>
<p class="font_8"><br></p>
<p class="font_8">Activated T cells rely heavily on aerobic glycolysis (the Warburg effect) to support rapid growth and effector function under oxygen-replete conditions. Under hypoxic conditions, cells shift toward anaerobic glycolysis, producing lactate without requiring oxygen, as oxidative phosphorylation becomes less efficient due to limited oxygen availability (Longo et al., 2025).</p>
<p class="font_8"><br></p>
<p class="font_8">Key metabolic adaptations observed in hypoxic T cells include:</p>
<p class="font_8">• increased glucose uptake and glycolytic flux</p>
<p class="font_8">• upregulation of glucose transporters such as GLUT1</p>
<p class="font_8">• shift from oxidative phosphorylation to anaerobic glycolysis</p>
<p class="font_8">• accumulation of biosynthetic metabolic intermediates</p>
<p class="font_8"><br></p>
<p class="font_8">These metabolic changes allow T cells to maintain effector functions such as cytokine production and proliferation under stress conditions. However, prolonged metabolic stress can impair mitochondrial function and contribute to T cell exhaustion (Liu et al., 2020; Li et al., 2025).</p>
<p class="font_8"><br></p>
<p class="font_8">Tumor cells themselves often consume large quantities of glucose and other nutrients, further limiting metabolic resources available to infiltrating immune cells (Scharping & Delgoffe, 2021). As a result, the ability of therapeutic T cells to maintain metabolic flexibility may be a critical determinant of their effectiveness in solid tumors.</p>
<p class="font_8"><br></p>
<h2 class="font_2">Implications for Cell Therapy</h2>
<p class="font_8"><br></p>
<p class="font_8">Many cell therapy manufacturing workflows expand T cells in standard culture conditions at ~21% oxygen. While these environments support robust proliferation, they differ substantially from the hypoxic conditions cells encounter following infusion into patients, and even from normal tissue physoxia (~3–7% O₂). This mismatch between manufacturing conditions and the in vivo tumor microenvironment may influence the metabolic state of therapeutic cells at the time of infusion.</p>
<p class="font_8"><br></p>
<p class="font_8">Cells conditioned exclusively under high-oxygen conditions may require significant metabolic reprogramming after entering hypoxic tumor environments. Hypoxia-driven PD-L1 upregulation within tumors may also limit the activity of infused T cells regardless of their intrinsic functional state, highlighting the importance of combining metabolic conditioning strategies with checkpoint blockade approaches.</p>
<p class="font_8"><br></p>
<p class="font_8">Recent research suggests that environmental conditioning during cell expansion may influence the metabolic phenotype, persistence, and functionality of therapeutic T cells (Corrado et al., 2022; Cunha et al., 2023). <a href="https://www.xcellbio.com/avatar-odyssey"><strong>Controlled oxygen environments during culture</strong></a> may therefore represent an important variable for optimizing cell therapy products.</p>
<p class="font_8"><br></p>
<h2 class="font_2">Looking Forward</h2>
<p class="font_8"><br></p>
<p class="font_8">The metabolic landscape of the tumor microenvironment presents both challenges and opportunities for the development of effective immunotherapies. As researchers continue to investigate the interplay between oxygen availability, metabolic programming, and immune cell function, <a href="https://www.xcellbio.com/technology"><strong>new strategies are emerging to improve the performance of cell-based therapies.</strong></a></p>
<p class="font_8"><br></p>
<p class="font_8">By integrating insights from immunometabolism with advances in cell manufacturing technology, it may become possible to better prepare therapeutic immune cells for the conditions they will encounter in patients. Continued exploration of hypoxia-driven metabolic pathways, including HIF-1α signaling, anaerobic glycolytic reprogramming, and checkpoint ligand regulation, will play a central role in shaping the next generation of cancer immunotherapies.</p>
<p class="font_8"><br></p>
<h2 class="font_2">Frequently Asked Questions</h2>
<p class="font_8"><br></p>
<h3 class="font_3">What is hypoxia in the tumor microenvironment?</h3>
<p class="font_8"><br></p>
<p class="font_8">Hypoxia refers to conditions where oxygen levels fall below those found in normal tissues. In solid tumors, rapid growth and abnormal vascularization often limit oxygen delivery, resulting in regions where oxygen concentrations may fall to 0.5–5%. These hypoxic regions significantly influence immune cell metabolism, tumor progression, and responses to therapy.</p>
<p class="font_8"><br></p>
<h3 class="font_3">How does hypoxia affect T cell metabolism?</h3>
<p class="font_8">Hypoxia alters T cell metabolism by stabilizing the transcription factor HIF-1α, which promotes glycolytic metabolism and regulates genes involved in energy production and cellular adaptation. While this metabolic shift can initially support T cell activation, prolonged hypoxia can contribute to metabolic stress, mitochondrial dysfunction, and reduced immune function.</p>
<p class="font_8"><br></p>
<h3 class="font_3">Why is hypoxia important for cancer immunotherapy?</h3>
<p class="font_8">T cells used in therapies such as CAR-T and TIL therapy must function within the tumor microenvironment after infusion. Because many tumors contain hypoxic regions, therapeutic immune cells must be able to adapt to low oxygen conditions. Cells that cannot maintain metabolic activity under hypoxia may lose persistence or become functionally exhausted.</p>
<p class="font_8"><br></p>
<h3 class="font_3">Do standard cell culture conditions mimic tumor oxygen levels?</h3>
<p class="font_8">Most laboratory cell culture systems operate under normoxic conditions (~21% oxygen), which differ significantly from the oxygen levels present in tumors. This mismatch means therapeutic cells expanded in standard culture environments may encounter a dramatic metabolic shift once introduced into hypoxic tumor tissues.</p>
<p class="font_8"><br></p>
<h3 class="font_3">Can oxygen levels during cell manufacturing influence therapeutic performance?</h3>
<p class="font_8">Emerging research suggests that environmental factors such as oxygen concentration during cell expansion can influence metabolic programming, differentiation state, and persistence of therapeutic T cells. <a href="https://www.xcellbio.com/foundry"><strong>Controlled oxygen environments during manufacturing may therefore </strong></a>represent an important parameter for optimizing cell therapy products.</p>
<h2 class="font_2"><br></h2>
<h2 class="font_2">References</h2>
<p class="font_8"><br></p>
<p class="font_8">Bigos, K.J.A. et al. (2024). Tumour response to hypoxia: understanding the hypoxic tumour microenvironment. Frontiers in Oncology.</p>
<p class="font_8">Cunha, P.P. et al. (2023). Oxygen levels at the time of activation determine T cell persistence and immunotherapeutic efficacy.</p>
<p class="font_8">Corrado, M. et al. (2022). Targeting memory T cell metabolism to improve immunity. Journal of Clinical Investigation.</p>
<p class="font_8">Li, F. et al. (2025). Mitochondrial metabolism in T-cell exhaustion. Cell Death & Disease.</p>
<p class="font_8">Liu, Y.N. et al. (2020). Hypoxia induces mitochondrial defects that promote T cell exhaustion. Nature Immunology.</p>
<p class="font_8">Longo, J. et al. (2025). Nutrient allocation fuels T-cell-mediated immunity. Cell Metabolism.</p>
<p class="font_8">Scharping, N.E., & Delgoffe, G.M. (2021). Tumor microenvironment metabolism and immunotherapy. Nature Reviews Immunology. [Note: journal attribution to be verified against original source.]</p>
<p class="font_8">Shen, H. et al. (2024). The HIF-1α–glycolysis axis regulates IFN-γ production in T cells under hypoxia. Nature Communications.</p>
<p class="font_8">Shi, S. et al. (2025). Research progress of HIF-1α in immunotherapy outcomes. Frontiers in Immunology.</p>
<p class="font_8">Vaupel, P., & Mayer, A. (2007). Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Reviews.</p>
<p class="font_8"><br></p>
<p class="font_7">Explore Hypoxic Cell Culture Systems<br>
<br>
Learn how AVATAR Odyssey enables precise control of oxygen conditions to model tumor microenvironments and improve T cell function.<br>
<br>
<a href="https://www.xcellbio.com/avatar-odyssey"><strong>Explore AVATAR Odyssey</strong></a> <a href="https://www.xcellbio.com/avatar-odyssey"><strong>→</strong></a></p>
<p class="font_8"><br></p>
<p class="font_8"><br></p>](https://static.wixstatic.com/media/7d1633_3cc3cbbcf6bd4f14bfabbf3a407248e5~mv2.png/v1/fill/w_824,h_300,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/Image-empty-state_edited.png)
INSIGHT • 10 MIN READ
Hypoxia and T Cell Function in the Tumor Microenvironment
Hypoxia is a defining feature of solid tumor microenvironments and strongly influences T cell metabolism, persistence, and effector function. This article explores how oxygen gradients shape immune responses and the implications for cell therapy development.
INSIGHT • 10 MIN READ
Metabolic Fitness as a Determinant of CAR-T Cell Persistence
Metabolic fitness plays a central role in CAR-T cell persistence and therapeutic durability. This article explores how mitochondrial function, metabolic programming, and manufacturing conditions shape long-term cell therapy performance.
![<h2 class="font_2">Engineering the Tumor Microenvironment During Cell Manufacturing</h2>
<h3 class="font_3"><br></h3>
<h2 class="font_2">Introduction</h2>
<p class="font_8"><br></p>
<p class="font_8">Cell therapies are typically manufactured under standardized ex vivo conditions designed to maximize expansion and viability. However, these conditions often differ substantially from the environments that therapeutic cells encounter after infusion, particularly within solid tumors.</p>
<p class="font_8">The tumor microenvironment (TME) is characterized by hypoxia, nutrient limitation, and metabolic stress, all of which can impair immune cell function. Increasingly, research suggests that exposing cells to more physiologically relevant conditions during manufacturing may improve their ability to function after infusion.</p>
<p class="font_8"><br></p>
<p class="font_8">This concept, engineering the cellular environment during manufacturing to better match in vivo conditions, represents a growing area of interest in cell therapy development.</p>
<p class="font_8"><br></p>
<h2 class="font_2">The Mismatch Between Manufacturing and In Vivo Environments</h2>
<p class="font_8"><br></p>
<p class="font_8">Standard cell culture conditions typically involve:</p>
<p class="font_8"><br></p>
<p class="font_8">• atmospheric oxygen (~21% O₂)</p>
<p class="font_8">• nutrient-rich media</p>
<p class="font_8">• static two-dimensional culture with no bioreactor-style mechanical inputs</p>
<p class="font_8">In contrast, solid tumor microenvironments often exhibit:</p>
<p class="font_8">• low oxygen levels (~0.2–4% O₂; median values typically below 2%)</p>
<p class="font_8">• nutrient deprivation</p>
<p class="font_8">• accumulation of metabolic by-products such as lactate</p>
<p class="font_8"><br></p>
<p class="font_8">It is worth noting that the mismatch extends beyond tumors specifically: normal peripheral tissue oxygen (physoxia) averages around 5% and ranges from approximately 3% to 7.4%, meaning standard culture conditions are metabolically mismatched with all in vivo environments, not only tumors (McKeown, 2014). This mismatch can result in T cells that are optimized for growth in vitro but less prepared for the metabolic constraints they encounter in vivo (Vaupel & Mayer, 2007; McKeown, 2014).</p>
<p class="font_8"><br></p>
<p class="font_8">As a result, cells expanded under conventional conditions may experience rapid functional decline following infusion into tumors.</p>
<p class="font_8"><br></p>
<h2 class="font_2">Hypoxia as a Key Environmental Signal</h2>
<p class="font_8"><br></p>
<p class="font_8">Hypoxia is one of the most defining features of solid tumors and plays a central role in shaping immune cell metabolism and function. Low oxygen levels stabilize hypoxia-inducible factors (HIFs), which activate transcription of genes encoding glucose transporters, glycolytic enzymes, pyruvate dehydrogenase kinase, and lactate dehydrogenase, collectively shifting cells away from oxidative phosphorylation and toward anaerobic glycolysis (Semenza, 2012).</p>
<p class="font_8">In T cells, hypoxia can influence:</p>
<p class="font_8"><br></p>
<p class="font_8">• metabolic pathway selection</p>
<p class="font_8">• differentiation state</p>
<p class="font_8">• effector function and persistence</p>
<p class="font_8"><br></p>
<p class="font_8">The effects of hypoxia on T cells are highly context-dependent. Importantly, research has shown that hypoxia alone does not necessarily drive T cell dysfunction; it is the combination of continuous stimulation under hypoxia that rapidly leads to exhaustion, mediated by Blimp-1-driven repression of mitochondrial biogenesis (Scharping et al., 2021). This distinction has direct implications for manufacturing: applying hypoxic conditions during active stimulation phases carries a different risk profile than applying them during rest or memory-formation phases.</p>
<p class="font_8"><br></p>
<p class="font_8"><a href="https://www.xcellbio.com/avatar-odyssey"><strong>Controlled hypoxic exposure</strong></a> at appropriate stages of manufacturing may therefore precondition T cells to better tolerate hypoxic tumor environments, though the timing, intensity, and duration of exposure require careful optimization (Corrado et al., 2022).</p>
<p class="font_8"><br></p>
<h2 class="font_2">Environmental Conditioning and Metabolic Programming</h2>
<p class="font_8"><br></p>
<p class="font_8">Beyond oxygen levels, multiple environmental factors can influence T cell metabolism during manufacturing, including:</p>
<p class="font_8"><br></p>
<p class="font_8">• nutrient availability (e.g., glucose, amino acids)</p>
<p class="font_8">• cytokine signaling</p>
<p class="font_8">• pH and metabolite accumulation</p>
<p class="font_8">• physical parameters such as pressure and gas composition</p>
<p class="font_8"><br></p>
<p class="font_8">These variables shape metabolic programming, which in turn influences differentiation into effector or memory-like states.</p>
<p class="font_8"><br></p>
<p class="font_8">For example, conditions that promote mitochondrial function and metabolic flexibility may support the generation of T cells with improved persistence. Conversely, overly stimulatory conditions may drive terminal differentiation and reduce long-term efficacy (Buck et al., 2015). Engineering these parameters in a controlled manner offers a potential strategy for improving therapeutic performance.</p>
<p class="font_8"><br></p>
<h2 class="font_2">Toward Physiologically Relevant Manufacturing Systems</h2>
<p class="font_8"><br></p>
<p class="font_8">There is growing interest in developing manufacturing systems that provide precise <a href="https://www.xcellbio.com/foundry"><strong>control over oxygen, pressure, and environmental parameters</strong></a> to better replicate in vivo conditions during cell expansion.</p>
<p class="font_8"><br></p>
<p class="font_8">Such systems aim to more closely replicate aspects of the tumor microenvironment or lymphoid tissues, enabling the generation of cells that are better adapted to their intended therapeutic context. This approach represents a shift from maximizing expansion alone to optimizing functional fitness and persistence.</p>
<p class="font_8"><br></p>
<h2 class="font_2">Implications for Next-Generation Cell Therapies</h2>
<p class="font_8"><br></p>
<p class="font_8">As cell therapies expand into solid tumor indications, overcoming the challenges of the tumor microenvironment becomes increasingly important. Engineering the manufacturing environment offers several potential advantages:</p>
<p class="font_8"><br></p>
<p class="font_8">• improved persistence of therapeutic cells</p>
<p class="font_8">• enhanced resistance to metabolic stress</p>
<p class="font_8">• better functional performance in hypoxic conditions</p>
<p class="font_8"><br></p>
<p class="font_8">By integrating environmental conditioning into manufacturing workflows, developers may be able to produce more effective and durable cell therapies.</p>
<p class="font_8"><br></p>
<h2 class="font_2">Looking Forward</h2>
<p class="font_8"><br></p>
<p class="font_8">The tumor microenvironment presents one of the most significant barriers to effective cell therapy in solid tumors. Bridging the gap between in vitro manufacturing conditions and in vivo environments, including the gap between 21% culture oxygen and the physoxic baseline of normal tissues, is an important step toward improving therapeutic outcomes.</p>
<p class="font_8"><br></p>
<p class="font_8">Advances in immunometabolism and bioprocessing technologies are enabling new approaches to environmental control during cell expansion, opening the door to more physiologically informed manufacturing strategies.</p>
<p class="font_8"><br></p>
<p class="font_8">As the field evolves, engineering the cellular environment, with careful attention to the timing and context of hypoxic exposure, nutrient conditions, and stimulation protocols, may become a central component of next-generation cell therapy development.</p>
<p class="font_8"><br></p>
<h2 class="font_2">Frequently Asked Questions</h2>
<p class="font_8"><br></p>
<h3 class="font_3">Why does the tumor microenvironment matter for cell therapy?</h3>
<p class="font_8">The tumor microenvironment contains conditions such as low oxygen, limited nutrients, and metabolic stress that can impair immune cell function. These factors can reduce the effectiveness and persistence of therapeutic cells.</p>
<p class="font_8"><br></p>
<h3 class="font_3">What is environmental conditioning in cell therapy manufacturing?</h3>
<p class="font_8">Environmental conditioning refers to controlling factors such as oxygen levels, nutrients, and physical parameters during cell expansion to influence T cell metabolism and function.</p>
<p class="font_8"><br></p>
<h3 class="font_3">Can hypoxia improve T cell therapies?</h3>
<p class="font_8">In some contexts, controlled exposure to low oxygen levels during manufacturing may help T cells adapt to hypoxic tumor environments. However, outcomes depend on how hypoxia is applied.</p>
<p class="font_8"><br></p>
<h3 class="font_3">How does manufacturing affect T cell persistence?</h3>
<p class="font_8">Manufacturing conditions influence metabolic programming and differentiation state. These factors determine whether T cells develop into short-lived effectors or long-lived memory-like cells.</p>
<p class="font_8"><br></p>
<h3 class="font_3">What is the advantage of physiologically relevant manufacturing systems?</h3>
<p class="font_8">Systems that better mimic in vivo conditions may produce cells that are more resilient, metabolically adaptable, and effective after infusion.</p>
<p class="font_8"><br></p>
<h2 class="font_2">References</h2>
<p class="font_8"><br></p>
<p class="font_8">Buck, M.D., O’Sullivan, D., & Pearce, E.L. (2015). T cell metabolism drives immunity. Journal of Experimental Medicine, 212(9), 1345–1360. [Corrected from “2017” in the original; the relevant review by these authors is the 2015 JEM paper.]</p>
<p class="font_8">Corrado, M. et al. (2022). Targeting memory T cell metabolism to improve immunity. Journal of Clinical Investigation. [Journal attribution to be independently verified.]</p>
<p class="font_8">McKeown, S.R. (2014). Defining normoxia, physoxia and hypoxia in tumours. The British Journal of Radiology, 87(1035), 20130676.</p>
<p class="font_8">Scharping, N.E. et al. (2021). Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nature Immunology, 22, 205–215.</p>
<p class="font_8">Semenza, G.L. (2012). Hypoxia-inducible factors in physiology and medicine. Cell, 148(3), 399–408.</p>
<p class="font_8">Vaupel, P., & Mayer, A. (2007). Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Reviews. [Note: original cited as “Cancer and Metastasis Reviews”; correct journal name is Cancer Metastasis Reviews.]</p>
<p class="font_8"><br></p>
<p class="font_8"><br></p>
<p class="font_7">Explore AVATAR Environmental Control Platforms<br>
<br>
Engineering the cellular environment during manufacturing is a powerful approach to improving cell therapy outcomes. AVATAR™ systems enable precise control of oxygen, pressure, and metabolic conditions across research and GMP workflows.<br>
<br>
Explore AVATAR Technology <a href="https://www.xcellbio.com/technology"><strong>→</strong></a></p>](https://static.wixstatic.com/media/7d1633_54cc3d5561514eababe7abc37b5f4f63~mv2.png/v1/fill/w_824,h_300,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/Image-empty-state_edited.png)
INSIGHT • 10 MIN READ
Engineering the Tumor Microenvironment During Cell Manufacturing
Engineering environmental conditions during cell manufacturing may improve T cell persistence and function. This article explores how hypoxia, metabolism, and controlled environments shape next-generation cell therapies.
Interested in applying these insights?
Book a demo or speak with our team about AVATAR™ systems.